Key facts
- It has raised $27.8M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Tech Incubator Program for Startup, Smilegate Investment, IMM Investment, Kiwoom Investment, Shinhan Capital — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for ImmunoForge
- ·The full record, as it builds
Funding rounds
No funding rounds for ImmunoForge are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ImmunoForge
Operator of a drug development and pharmaceutical company intended to develop drugs for treating sarcopenia and cancer. The company's drugs specialize in targeting Duchenne muscular dystrophy, ALS, senile sarcopenia, polymyositis, cancer cachexia, and genomically defined rare cancers such as chronic myelogenous leukemia, enabling pharmaceutical companies to develop biologics with reduced dosing frequency and improved patient adherence.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2017
- Employees
- 17
- Website
- immunoforge.com/
- Ownership
- Privately Held (backing)
ImmunoForge doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ImmunoForge shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ImmunoForge in its N-PORT filings yet. We sweep new filings monthly.